Compare Davita Inc (DVA) vs The Coca-Cola Co K (KO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs The Coca-Cola Co K — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while The Coca-Cola Co K trades at $87.39 (market cap $377.63B). The key difference: The Coca-Cola Co K is far larger — about 33.4× Davita Inc's market cap, and The Coca-Cola Co K pays a 2.42% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and The Coca-Cola Co K for 154 Days on average.
| DVA | KO | |
|---|---|---|
Market Cap | $11.29B | $377.63B |
Volume | 582,204 | 14,894,568 |
Sector | Health | Consumer Staples |
52-Week High | $240.96 | $91.99 |
52-Week Low | $103.87 | $66.37 |
Typical Hold Time | 113 Days | 154 Days |
Enterprise Value | $24.01B | $404.81B |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
Coca-Cola (KO) trades at $85.82, down 0.41% on the day, with a bearish technical signal despite strong fundamental performance. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.97 exceeding expectations. KO maintains robust profitability with 61.89% gross margins and 28.56% net income margins, supported by steady revenue growth and a dominant market position.
The stock presents a compelling dividend opportunity with 64 consecutive years of increases, though technical indicators suggest near-term pressure. Analyst consensus remains bullish with a $95.75 price target, representing 11.6% upside potential. Key risks include regional demand divergence and high valuation multiples that may limit short-term appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
